These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26023014)

  • 41. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Phosphate binder up to date].
    Shigematsu T; Sakaguchi T; Orita H
    Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
    Cozzolino M; Brancaccio D
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical experiences of bixalomer usage at our hospital.
    Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of prolonged administration of lanthanum carbonate in dialysis patients.
    Gotoh J; Kukita K; Tsuchihashi S; Hattori M; Iida J; Horie T; Onodera K; Furui H; Tamaki T; Meguro J; Yonekawa M; Kawamura A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():9-14. PubMed ID: 23586507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):287-298. PubMed ID: 30664365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
    Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
    Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Radiographic characteristics of lanthanum carbonate absorption].
    Vrigneaud L; Lefèbvre D; Daem AO; Lemaitre V
    Nephrol Ther; 2008 Apr; 4(2):111-3. PubMed ID: 18243834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.